Combination of atezolizumab and chidamide to maintain long-term remission in refractory metastatic extranodal natural killer/T-cell lymphoma: A case report-Reference-Cited by-同舟云学术

Combination of atezolizumab and chidamide to maintain long-term remission in refractory metastatic extranodal natural killer/T-cell lymphoma: A case report

Published:2022-02-16 Issue:5 Volume:10 Page:1609-1616
ISSN:2307-8960
Container-title:World Journal of Clinical Cases
language:
Short-container-title:WJCC

Author:

Wang Juan,Gao Yong-Sheng,Xu Kun,Li Xiao-Dong

Publisher

Baishideng Publishing Group Inc.

Subject

General Medicine

Reference26 articles.

1. Current status and progress of lymphoma management in China

2. Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases

3. Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project

4. Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease

5. Sustained remission of multi-line relapsed extranodal NK/T-cell lymphoma, nasal type, following sintilimab and chidamide

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epigenetic alterations and advancement of lymphoma treatment;Annals of Hematology;2023-08-15

2. Rational Targets of Therapy in Extranodal NK/T-Cell Lymphoma;Cancers;2023-02-21

3. Treatment of extranodal NK/T-cell lymphoma: From past to future;Frontiers in Immunology;2023-02-07

4. Multiple drugs;Reactions Weekly;2022-05